Eli Lilly and Company announced a $1 billion expansion of its Limerick, Ireland, manufacturing facility, boosting production of biologic active ingredients, including treatments for early-stage Alzheimer’s disease.
The Indianapolis-based company also completed an $800 million facility in Kinsale, Ireland, which has been producing diabetes and obesity medicines since last year.
The Limerick site, expected to begin operations in 2026, will support Lilly’s Alzheimer's disease portfolio and other biologic drugs. "These investments will boost the production of some of our medicines, helping millions of people," said Edgardo Hernandez, Lilly’s executive vice president and head of manufacturing operations.
The additional Limerick investment doubles Lilly’s initial commitment and will create 150 new jobs, bringing the total to 450 employees. The project remains subject to planning approval.
The expansion at Lilly’s Kinsale site, which was recognized by the International Society of Pharmaceutical Engineers for innovation, will utilize advanced digital and continuous manufacturing technology.
Lilly also emphasized sustainability in its Ireland operations, noting plans to reduce energy use by 35%, water consumption by 40%, and waste generation by 15% at the Limerick site. The company operates Ireland’s largest privately-owned solar farm in Kinsale.
Since 2020, Lilly has invested over $20 billion globally to expand its manufacturing capabilities.
